Advertisement
BSX vs MMSI
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Merit Medical Systems (MMSI) Stock Comparison
Key Takeaways
- Boston Scientific (BSX) is a larger medical device company with diversified product lines, while Merit Medical Systems (MMSI) focuses on specialized interventional and diagnostic tools.
- Recent market activity shows BSX trading near the lower end of its 52-week range amid product recall concerns, whereas MMSI has posted modest short-term gains despite year-to-date declines.
- Both companies are preparing to report second-quarter 2026 results in late July, providing near-term catalysts for investor sentiment.
- BSX exhibits lower volatility (beta of 0.58) compared to broader market movements than MMSI (beta of 0.52), reflecting differences in scale and business exposure.
- Sector headwinds including regulatory scrutiny affect both stocks, though BSX benefits from broader analyst coverage and institutional ownership levels around 89%.
- Relative positioning highlights trade-offs between established scale at BSX and niche growth opportunities at MMSI.
Introduction
This comparison examines Boston Scientific Corporation (BSX) and Merit Medical Systems, Inc. (MMSI), two publicly traded companies in the medical devices sector. Investors and traders interested in healthcare equities may find this analysis relevant for evaluating relative performance, business models, and market positioning within a volatile industry environment. The article focuses on recent developments to provide objective context for assessing these stocks side by side.
BSX Overview and Recent Performance
Boston Scientific Corporation (BSX) develops and markets a wide range of medical devices used in cardiovascular, rhythm management, endoscopy, and neuromodulation procedures. In recent market activity, the stock has traded around the $44 level, reflecting pressure from product recalls and regulatory scrutiny that have weighed on sentiment. Analysts project second-quarter 2026 earnings per share of approximately $0.83 on revenue of $5.39 billion, with the report scheduled for July 29. Broader performance metrics indicate the shares have declined notably from earlier 52-week highs, though institutional ownership remains substantial and multiple firms maintain buy ratings despite several target price adjustments.
MMSI Overview and Recent Performance
Merit Medical Systems, Inc. (MMSI) specializes in the design and manufacture of disposable medical devices for interventional cardiology, radiology, and other procedural areas. Recent trading has placed the stock near $74, with modest gains observed over the past month amid year-to-date declines of approximately 15.7%. The company is set to release second-quarter 2026 results on July 30. Product expansion initiatives have drawn attention, supporting short-term momentum even as broader sector dynamics and analyst target revisions influence positioning. Institutional ownership exceeds 99%, underscoring sustained professional interest.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of its hundreds of AI trading bots that operate across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this section. Available bots feature varied trading styles, strategies, timeframes, performance statistics, and ticker sets, allowing users to explore options suited to different risk tolerances and objectives. This resource provides factual data on bot metrics to support informed evaluation. Explore the full range at Trending AI Robots.
Head-to-Head Comparison
Boston Scientific (BSX) operates a diversified business model spanning multiple therapeutic areas, providing broader exposure within the medical devices sector, while Merit Medical Systems (MMSI) maintains a more focused portfolio centered on interventional and diagnostic products. Growth drivers for BSX include established product pipelines and international reach, contrasted with MMSI’s emphasis on procedural innovations and expansion announcements. Recent momentum favors MMSI in the short term, yet BSX demonstrates greater scale and lower observed volatility. Risk factors for both include regulatory and recall-related pressures, though BSX faces heightened scrutiny in specific product lines. Market sentiment reflects analyst optimism tempered by price target reductions across the sector, with BSX benefiting from more extensive coverage.
Tickeron AI Verdict
Based on observable factors such as trend consistency, scale, and relative positioning ahead of earnings, Tickeron’s AI would likely assign a probabilistic edge to Boston Scientific (BSX) in the current environment due to its larger market capitalization, diversified operations, and established institutional backing, though Merit Medical Systems (MMSI) shows competitive short-term resilience that could narrow the gap depending on upcoming results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a Buy and MMSI is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green whileMMSI’s FA Score has 0 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- MMSI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 4 TA indicator(s) are bullish while MMSI’s TA Score has 3 bullish TA indicator(s).
- BSX’s TA Score: 4 bullish, 3 bearish.
- MMSI’s TA Score: 3 bullish, 4 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а +5.60% price change this week, while MMSI (@Pharmaceuticals: Other) price change was +14.38% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.03%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -1.71%.
Reported Earning Dates
BSX is expected to report earnings on Oct 28, 2026.
MMSI is expected to report earnings on Oct 22, 2026.
Industries' Descriptions
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+5.03% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BSX | MMSI | BSX / MMSI | |
| Capitalization | 69.5B | 5.08B | 1,369% |
| EBITDA | 5.49B | 362M | 1,517% |
| Gain YTD | -50.991 | -3.551 | 1,436% |
| P/E Ratio | 18.92 | 34.98 | 54% |
| Revenue | 20.6B | 1.58B | 1,305% |
| Total Cash | 1.45B | 449M | 324% |
| Total Debt | 11B | 820M | 1,341% |
BSX | MMSI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 95 | 74 | |
SMR RATING 1..100 | 59 | 75 | |
PRICE GROWTH RATING 1..100 | 64 | 39 | |
P/E GROWTH RATING 1..100 | 98 | 72 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MMSI's Valuation (67) in the Medical Specialties industry is in the same range as BSX (68). This means that MMSI’s stock grew similarly to BSX’s over the last 12 months.
MMSI's Profit vs Risk Rating (74) in the Medical Specialties industry is in the same range as BSX (95). This means that MMSI’s stock grew similarly to BSX’s over the last 12 months.
BSX's SMR Rating (59) in the Medical Specialties industry is in the same range as MMSI (75). This means that BSX’s stock grew similarly to MMSI’s over the last 12 months.
MMSI's Price Growth Rating (39) in the Medical Specialties industry is in the same range as BSX (64). This means that MMSI’s stock grew similarly to BSX’s over the last 12 months.
MMSI's P/E Growth Rating (72) in the Medical Specialties industry is in the same range as BSX (98). This means that MMSI’s stock grew similarly to BSX’s over the last 12 months.
| BSX | MMSI | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 61% | 3 days ago 41% |
| Stochastic ODDS (%) | 3 days ago 50% | 3 days ago 56% |
| Momentum ODDS (%) | 3 days ago 57% | N/A |
| MACD ODDS (%) | N/A | 3 days ago 78% |
| TrendWeek ODDS (%) | 3 days ago 55% | 3 days ago 59% |
| TrendMonth ODDS (%) | 3 days ago 55% | 3 days ago 56% |
| Advances ODDS (%) | 6 days ago 57% | 3 days ago 65% |
| Declines ODDS (%) | 4 days ago 55% | 12 days ago 57% |
| BollingerBands ODDS (%) | N/A | 3 days ago 42% |
| Aroon ODDS (%) | 3 days ago 69% | 3 days ago 50% |
Advertisement